Operating cash flow of $4.7B covered $853M of dividends in 2026Q3, but quarterly OCF swung from a $745M outflow in 2024Q3 to $6.3B in 2026Q2, indicating uneven float generation and reliance on operating cash for capital returns.
CVS Health Corp. (CVS) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 18.71B | 10.64B | 9.11B | 13.43B | 16.18B | 18.27B | 15.87B | 12.85B | 8.87B | 8.01B | 10.14B | 8.54B | 8.14B | 5.78B | 6.67B | 5.86B | 4.78B | 4.04B | 3.95B | 3.23B | 1.74B | 1.61B | 914.2M | 968.9M | 1.2B | 680.6M | 780.2M | 726.3M | 292.4M | -105.8M | 327.2M |
| Operating CF Growth % | 803.46% | 16.82% | -32.17% | -17.01% | -11.43% | 15.13% | 23.48% | 44.93% | 10.72% | -21.04% | 18.76% | 4.94% | 40.71% | -13.31% | 13.92% | 22.54% | 18.44% | 2.23% | 22.21% | 85.36% | 8.08% | 76.34% | -5.65% | -19.58% | 77.02% | -12.77% | 7.42% | 148.39% | 376.37% | -132.34% | -28.87% |
| Operating CF / Revenue % | 4.45% | 2.65% | 2.44% | 3.75% | 5.02% | 6.25% | 5.9% | 5% | 4.56% | 4.33% | 5.71% | 5.57% | 5.84% | 4.56% | 5.42% | 5.47% | 4.99% | 4.11% | 4.51% | 4.23% | 3.98% | 4.36% | 2.99% | 3.64% | 4.98% | 3.06% | 3.88% | 4.01% | 1.91% | -0.77% | 2.77% |
| Net Income | 11.05B | 1.73B | 4.59B | 8.37B | 4.33B | 7.99B | 7.19B | 6.63B | -596M | 6.62B | 5.32B | 5.24B | 4.64B | 4.59B | 3.86B | 3.46B | 3.42B | 3.7B | 3.21B | 2.64B | 1.37B | 1.22B | 959.3M | 847.3M | 716.6M | 413.2M | 746M | 635.1M | 384.5M | 105.9M | 208.2M |
| Depreciation & Amortization | 4.52B | 4.61B | 4.6B | 4.37B | 4.22B | 4.49B | 4.44B | 4.37B | 2.72B | 2.48B | 2.48B | 2.09B | 1.93B | 1.87B | 1.75B | 1.57B | 1.47B | 1.39B | 1.27B | 1.09B | 733.3M | 589.1M | 439.9M | 341.7M | 310.3M | 320.8M | 296.6M | 277.9M | 249.7M | 242.6M | 262.8M |
| Stock-Based Compensation | 610M | 535M | 540M | 588M | 447M | 484M | 400M | 453M | 280M | 234M | 222M | 230M | 165M | 141M | 132M | 135M | 150M | 165M | 92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 198M | 102M | -572M | -676M | -2.03B | -402M | -570M | -654M | 87M | -1.33B | 18M | -252M | -58M | -86M | -111M | 144M | 30M | 48M | -3M | 40.1M | 98.2M | 13.5M | -7.2M | 41.1M | 71.8M | -83.5M | 43.8M | 124.8M | 80.6M | -140.4M | 116.4M |
| Other Non-Cash Items | -221M | 5.14B | -153M | 765M | 2.39B | 1.85B | 1.24B | 548M | 6.49B | 421M | 778M | -14M | 521M | 0 | 348M | -53M | 0 | 0 | 0 | 78M | 69.9M | 0 | 0 | 0 | 0 | 352.5M | 0 | 0 | 188.6M | 466.4M | 146.6M |
| Working Capital Changes | 2.54B | -1.47B | 109M | 15M | 6.82B | 3.86B | 3.16B | 1.5B | -112M | -416M | 1.33B | 1.24B | 934M | -734M | 687M | 604M | -294M | -1.26B | -628M | -620M | -527.9M | -215.2M | -477.8M | -261.2M | 106.1M | -322.4M | -306.2M | -311.5M | -611M | -780.3M | -406.8M |
| Cash from Investing | -7.54B | -5.87B | -7.61B | -20.89B | -5.05B | -5.26B | -5.53B | -3.34B | -43.28B | -2.88B | -2.47B | -13.42B | -4.04B | -1.83B | -1.85B | -2.41B | -1.64B | -1.07B | -4.58B | -3.08B | -4.59B | -911.6M | -3.16B | -753.6M | -735.8M | -536.8M | -640.5M | -566.4M | -585.4M | 160.8M | 23.4M |
| Capital Expenditures | -3.14B | -2.83B | -2.78B | -3.03B | -2.73B | -2.52B | -2.44B | -2.46B | -2.04B | -1.92B | -2.22B | -2.37B | -2.14B | -1.98B | -2.03B | -1.87B | -2B | -2.55B | -2.18B | -1.81B | -1.77B | -1.5B | -1.35B | -1.12B | -1.11B | -713.6M | -695.3M | -722.7M | -502.3M | -341.6M | -702.8M |
| Acquisitions | -22M | -436M | -95M | -16.61B | -1.39B | -146M | -26M | -444M | -41.39B | -1.18B | -524M | -11.47B | -2.44B | -415M | -371M | -1.19B | -177M | -101M | -2.65B | -1.98B | -4.22B | 0 | -2.29B | -133.1M | -93.5M | -159.1M | -263.3M | -101.1M | -133.6M | 0 | 0 |
| Purchase of Investments | -17.56B | -15.01B | -15.19B | -9.04B | -7.75B | -9.96B | -9.64B | -7.53B | -692M | -137M | -80M | -267M | -157M | -226M | 0 | -3M | 0 | -5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sale/Maturity of Investments | 13.13B | 12.38B | 10.35B | 7.73B | 6.73B | 7.25B | 6.47B | 7.05B | 817M | 61M | 91M | 243M | 161M | 136M | 0 | 60M | 1M | 0 | 232M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 309.7M | 485.8M |
| Other Investing | 54M | 26M | 101M | 68M | 85M | 122M | 101M | 47M | 21M | 298M | 267M | 446M | 526M | 654M | 552M | 596M | 541M | 1.58B | 19M | 706.9M | 1.4B | 583.8M | 478.1M | 501.2M | 466.5M | 335.9M | 318.1M | 257.4M | 50.5M | 192.7M | 240.4M |
| Cash from Financing | -8.57B | -4.94B | -1.14B | 2.68B | -10.52B | -11.36B | -7.7B | -7.65B | 36.82B | -6.75B | -6.76B | 4.88B | -5.69B | -1.24B | -4.86B | -3.46B | -2.8B | -3.23B | 929M | 377.9M | 2.87B | -579.4M | 1.8B | -72.5M | -4.9M | -244.8M | -32.4M | -110.7M | 281.3M | -369.3M | -24.7M |
| Dividends Paid | -3.42B | -3.4B | -3.37B | -3.13B | -2.91B | -2.63B | -2.62B | -2.6B | -2.04B | -2.05B | -1.84B | -1.58B | -1.29B | -1.1B | -829M | -674M | -479M | -439M | -383M | -322.4M | -140.9M | -131.6M | -119.8M | -105.2M | -104.9M | -105.2M | -104.8M | -104.7M | -102.5M | -87.6M | -137.5M |
| Share Repurchases | 0 | 0 | -3.02B | -2.01B | -3.5B | 0 | 0 | 0 | 0 | -4.36B | -4.46B | -5B | -4B | -3.98B | -4.33B | -3B | -1.5B | -2.48B | -23M | -5.37B | 0 | 0 | 0 | 0 | 0 | -129M | -163.2M | 0 | 0 | 0 | 0 |
| Stock Issued | 425M | 394M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 327.8M | 552.4M | 187.6M | 178.4M | 129.8M | 38.3M | 34M | 47.3M | 97.8M | 20.4M | 121.1M | 169.1M | 128.5M |
| Debt Issuance (Net) | -4M | -1000K | 1000K | 1000K | -1000K | -1000K | -1000K | -1000K | 1000K | -1000K | -1000K | 1000K | -1000K | 1000K | -1000K | -1000K | -1000K | -1000K | 1000K | 1000K | 1000K | -1000K | 1000K | -1000K | 1000K | -1000K | 1000K | -1000K | 1000K | -1000K | 1000K |
| Other Financing | -247M | 1.96B | 202M | -105M | 102M | 536M | 601M | 269M | 592M | 257M | 154M | 238M | 527M | 562M | 838M | 424M | 308M | 266M | 381M | 97.8M | 42.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25.8M |
| Net Change in Cash | 2.53B | -172M | 359M | -4.78B | 614M | 1.65B | 2.63B | 1.85B | 2.4B | -1.62B | 912M | -22M | -1.61B | 2.71B | -38M | -14M | 341M | -266M | 296M | 525.9M | 17.3M | 121.1M | -450.9M | 142.8M | 464.1M | -101M | 107.3M | 49.2M | -11.7M | -314.3M | -180.9M |
| Exchange Rate Effect | -62M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4M | 1M | 2M | -20M | -6M | 3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 11.54B | 8.88B | 8.53B | 13.3B | 12.69B | 11.04B | 8.41B | 6.55B | 1.9B | 3.52B | 2.61B | 2.48B | 4.09B | 1.38B | 1.41B | 1.43B | 1.09B | 1.35B | 1.06B | 530.7M | 513.4M | 392.3M | 843.2M | 700.4M | 236.3M | 337.3M | 230M | 180.8M | 192.5M | 506.8M | 180.9M |
| Cash at End | 11.95B | 8.71B | 8.88B | 8.53B | 13.3B | 12.69B | 11.04B | 8.41B | 4.29B | 1.9B | 3.52B | 2.46B | 2.48B | 4.09B | 1.38B | 1.41B | 1.43B | 1.09B | 1.35B | 1.06B | 530.7M | 513.4M | 392.3M | 843.2M | 700.4M | 236.3M | 337.3M | 230M | 180.8M | 192.5M | 0 |
| Free Cash Flow | 15.57B | 7.81B | 6.33B | 10.39B | 13.45B | 15.74B | 13.43B | 10.39B | 6.83B | 6.09B | 7.92B | 6.17B | 6B | 3.8B | 4.64B | 3.98B | 2.77B | 1.49B | 1.77B | 1.42B | -26.5M | 116.7M | -433.5M | -152.8M | 96M | -33M | 84.9M | 3.6M | -209.9M | -447.4M | -375.6M |
| FCF Growth % | 147.37% | 23.41% | -39.14% | -22.71% | -14.58% | 17.26% | 29.23% | 52.18% | 12.14% | -23.09% | 28.27% | 2.85% | 57.96% | -18.14% | 16.49% | 43.62% | 86.55% | -15.85% | 24.05% | 5475.09% | -122.71% | 126.92% | -183.7% | -259.17% | 390.91% | -138.87% | 2258.33% | 101.72% | 53.08% | -19.12% | -445.14% |
| FCF Margin % | 3.7% | 1.94% | 1.7% | 2.91% | 4.17% | 5.39% | 5% | 4.05% | 3.51% | 3.3% | 4.46% | 4.03% | 4.31% | 3% | 3.77% | 3.72% | 2.9% | 1.51% | 2.02% | 1.87% | -0.06% | 0.32% | -1.42% | -0.57% | 0.4% | -0.15% | 0.42% | 0.02% | -1.37% | -3.25% | -3.17% |
| FCF per Share | 12.06 | 6.14 | 5.01 | 8.06 | 10.17 | 11.85 | 10.22 | 7.96 | 6.54 | 5.95 | 7.34 | 5.48 | 5.13 | 3.1 | 3.63 | 2.96 | 2.01 | 1.03 | 1.2 | 1.04 | -0.03 | 0.14 | -0.53 | -0.19 | 0.12 | -0.04 | 0.11 | 0 | -0.26 | -0.57 | -0.88 |
Quick answers to the most common questions about buying CVS stock.
CVS Health Corp. (CVS) generated $10.64B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
CVS Health Corp. (CVS) generated $7.81B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
CVS Health Corp. (CVS) spent $2.83B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, CVS Health Corp. (CVS) returned $3.40B to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Regulatory scrutiny of vertical integration
Metrics are mathematically derived from official filings.
Float Generation Turns Volatile Quarterly
Based on EDBL's reported figures, CVS operating cash flow ranged from a $745M outflow in 2024Q3 to $6.3B in 2026Q2, with OCF to net income ratios swinging between -8.56 and 2.56, suggesting underwriting float generation is uneven rather than structurally reliable.
The swing from negative operating cash in 2024Q3 to peak inflows in 2026Q2 indicates that premium collection timing and claims payment timing are not stable enough to treat the quarterly float as a dependable funding source. Claims and losses of roughly $78B to $94B per quarter dwarf the operating cash line, so modest timing shifts in medical cost payments can move OCF materially. Investors should monitor whether the recent run of OCF exceeding net income reflects genuine float expansion or temporary working capital timing.
Investment Portfolio Runs Net Liquidating
According to recent SEC filings, CVS sold or matured investments of $2.7B to $4.2B in most recent quarters against purchases of $3.9B to $5.9B, a pattern that suggests the portfolio has been a net cash user rather than a source of funding.
Purchases exceeding sales in most quarters point to ongoing reinvestment of float into the portfolio rather than liquidation to fund operations. The 2026Q1 period, where sales of $4.2B roughly matched purchases of $4.2B, appears to be the exception rather than a new trend. This pattern warrants further investigation into the yield profile of new allocations given the thin net margin of 0.44%.
Dividend Coverage Depends on Operating Cash
Based on reported figures, quarterly dividends of roughly $838M to $878M were paid consistently, while buybacks were negligible at under $3M, meaning capital returns rest almost entirely on operating cash generation.
The dividend has been held nearly flat across ten quarters despite volatile operating cash, which means the coverage ratio tightens sharply in quarters like 2025Q3 when OCF turned slightly negative at $796M. With a debt-to-equity ratio of 1.24 and a 2.3% ROE, the capacity to maintain the payout through a prolonged OCF shortfall appears limited. Investors should monitor whether the payout remains covered across full-year cash flow rather than individual quarters.
Net Income Volatility Versus Cash Reality
As reported in financial statements, CVS posted a $4.0B net loss in 2025Q3 while still generating $796M of operating cash, and then reported $2.2B net income in 2026Q3 alongside $4.7B of operating cash, a divergence that warrants scrutiny of accrual quality.
The gap between net income and operating cash in both directions suggests that reserve adjustments and non-cash charges are significantly shaping reported earnings. A large GAAP loss paired with positive operating cash implies the 2025Q3 loss was largely non-cash, consistent with reserve or impairment charges rather than cash deterioration. Conversely, the 2026Q3 profit may partly reflect favorable reserve development that does not indicate durable cash generation.
Cash Strength May Mask Reserve Risk
Based on EDBL's reported figures, CVS's strong 2026Q2 operating cash of $6.3B against $3.0B net income may overstate durable cash generation, since claims and losses of $90.3B that quarter could embed reserve timing effects not visible in the cash line.
A period of OCF running well above net income can reflect reserve builds or delayed claim payments rather than structural float expansion, which would reverse as claims settle. The cash flow statement alone does not reveal the adequacy of medical claims reserves or reinsurance recoverables, so the apparent cash strength should be treated as provisional. Investors should monitor whether subsequent quarters sustain OCF above net income once reserve development is isolated.